Rituximab Infusion

DRUG3 trials

Sponsors

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Wake Forest University Health Sciences, Centre Hospitalier Universitaire de Saint Etienne

Conditions

Anti-MAG NeuropathyAutoimmune DiseaseGlomerular DiseaseMembranous GlomerulonephritisMultiple SclerosisNephrotic SyndromeProteinuria

Phase 2

Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

RecruitingNCT00977977

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Autoimmune Disease, Glomerular Disease, Membranous Glomerulonephritis +2

Start: 2010-12-22End: 2027-12-31Target: 30Updated: 2026-09-16

Phase 3

Rituximab Therapy in Anti-Myelin Associated Glycoprotein Patients With Characteristics of Good Responders

RecruitingNCT05136976

Centre Hospitalier Universitaire de Saint EtienneAnti-MAG Neuropathy

Start: 2023-06-29End: 2028-12-31Target: 90Updated: 2025-11-24

Phase 4

Study Evaluating Rapid Infusion Rituximab in Patients With Autoimmune Diseases

CompletedNCT02040116

Wake Forest University Health SciencesMultiple Sclerosis

Start: 2013-02-28End: 2014-08-31Updated: 2018-09-07

Related Papers

Prediagnostic Appearance of Thrombospondin Type-1 Domain 7A Autoantibodies in Membranous Nephropathy

Kidney3602022-11-298 citations